QIAGEN’s new dPCR portfolio – overcoming the current throughput, speed and usability bottlenecks in digital PCR.

Learn more about digital PCR technology

Digital PCR (dPCR) is a highly viable solution for copy number variation (CNV) detection, rare mutation detection and quantification, validation of NGS results, and applications alike. It offers significant advantages over quantitative PCR (qPCR) with regards to precision, reproducibility, and sensitivity, coupled with the ability to obtain absolute quantitative results without the need for standard curves. That is why, over the last years, many researchers have come to use dPCR, resulting in over 4500 publications until the previous year.

However, currently available solutions are either very complex to operate, or lack a scalability option for users with variable throughput and flexible workflow needs.

Unlike current systems relying on droplet generation, QIAGEN’s offering of fully integrated walkaway instrument options and multiple plate configurations with increased partitions can potentially solve throughput, speed, and usability challenges.

In this webinar, we’ll discuss:

  • What improvements does QIAGEN’s dPCR solution offer over existing systems
  • First insights into our entire dPCR product portfolio
  • The menu of dPCR assays and their availability roadmap

Dr. Michael Bussmann

Associate Director, Digital PCR Assays, QIAGEN GmbH
Dr. Gerald Schock, Associate Director, Digital PCR Instruments, QIAGEN GmbH

Gerald Schock

Gerald Schock studied Biology and Biochemistry at the University of Mainz, Germany and at the University College of Wales, Aberystwyth, UK. He joined QIAGEN after receiving his Ph.D. in 1996, and has held positions in Sales, Regional Marketing, and Global Marketing, where he built up the epigenetics portfolio including Pyrosequencing instruments before assuming responsibility for the Life Science detection portfolio, and has now transitioned into digital PCR.